Lymphatic Filariases
7
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
29%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Integrating Mental Health Into Neglected Tropical Disease Care in Ghana
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Prevalence of LF Infection in Districts Not Included in LF Control Activities